{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:28:44Z","timestamp":1790792924699,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,21]]},"DOI":"10.7759\/cureus.27109","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T16:43:12Z","timestamp":1658421792000},"source":"Crossref","is-referenced-by-count":4,"title":["Current Trends in the Management of Epithelial Lacrimal Gland Tumors: A Retrospective National Cancer Database Analysis"],"prefix":"10.7759","author":[{"given":"Prashanth","family":"Ashok Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Paulraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abirami","family":"Sivapiragasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2014.2846","article-title":"Epidemiology and treatment of lacrimal gland tumors: a population-based cohort analysis","volume":"140","author":"Mallen-St Clair J","year":"2014","unstructured":"Mallen-St Clair J, Arshi A, Tajudeen B, Abemayor E, St John M. Epidemiology and treatment of lacrimal gland tumors: a population-based cohort analysis. JAMA Otolaryngol Head Neck Surg. 2014, 140:1110-6. 10.1001\/jamaoto.2014.2846","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.22608\/APO.201707","article-title":"An update on tumors of the lacrimal gland","volume":"6","author":"Andreasen S","year":"2017","unstructured":"Andreasen S, Esmaeli B, Holstein SL, Mikkelsen LH, Rasmussen PK, Heegaard S. An update on tumors of the lacrimal gland. Asia Pac J Ophthalmol (Phila). 2017, 6:159-72. 10.22608\/APO.201707","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000531","article-title":"Management of lacrimal gland carcinoma: lessons from the literature in the past 40 years","volume":"32","author":"Woo KI","year":"2016","unstructured":"Woo KI, Yeom A, Esmaeli B. Management of lacrimal gland carcinoma: lessons from the literature in the past 40 years. Ophthalmic Plast Reconstr Surg. 2016, 32:1-10. 10.1097\/IOP.0000000000000531","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0026","article-title":"NCCN guidelines insights: head and neck cancers, version 1.2018","volume":"16","author":"Colevas AD","year":"2018","unstructured":"Colevas AD, Yom SS, Pfister DG, et al.. NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw. 2018, 16:479-90. 10.6004\/jnccn.2018.0026","journal-title":"J Natl Compr Canc Netw"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000515","article-title":"Overview of benign and malignant lacrimal gland tumors","volume":"29","author":"G\u00fcnd\u00fcz AK","year":"2018","unstructured":"G\u00fcnd\u00fcz AK, Ye\u015filta\u015f YS, Shields CL. Overview of benign and malignant lacrimal gland tumors. Curr Opin Ophthalmol. 2018, 29:458-68. 10.1097\/ICU.0000000000000515","journal-title":"Curr Opin Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000301","article-title":"Current treatment of lacrimal gland carcinoma","volume":"27","author":"Woo KI","year":"2016","unstructured":"Woo KI, Kim YD, Sa HS, Esmaeli B. Current treatment of lacrimal gland carcinoma. Curr Opin Ophthalmol. 2016, 27:449-56. 10.1097\/ICU.0000000000000301","journal-title":"Curr Opin Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for outcomes research: a review","volume":"3","author":"Boffa DJ","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, et al.. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017, 3:1722-8. 10.1001\/jamaoncol.2016.6905","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03525-6","article-title":"Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study","volume":"147","author":"Ashok Kumar P","year":"2021","unstructured":"Ashok Kumar P, Paulraj S, Wang D, Huang D, Sivapiragasam A. Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study. J Cancer Res Clin Oncol. 2021, 147:2447-58. 10.1007\/s00432-021-03525-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref9","unstructured":"International Association of Cancer Registries. International classification of diseases for oncology (ICD-O). (2021). Accessed: May 7:  http:\/\/www.iacr.com.fr\/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577."},{"key":"ref10","unstructured":"SEER ICD-O-3 Coding Materials. ICD-O-3 guidelines. (2021). Accessed: May 7: https:\/\/seer.cancer.gov\/icd-o-3\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e31829f3a0c","article-title":"Clinicopathologic review of epithelial tumors of the lacrimal gland","volume":"29","author":"Chawla B","year":"2013","unstructured":"Chawla B, Kashyap S, Sen S, et al.. Clinicopathologic review of epithelial tumors of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2013, 29:440-5. 10.1097\/IOP.0b013e31829f3a0c","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.76.7.401","article-title":"Primary malignant neoplasms of the lacrimal gland","volume":"76","author":"Wright JE","year":"1992","unstructured":"Wright JE, Rose GE, Garner A. Primary malignant neoplasms of the lacrimal gland. Br J Ophthalmol. 1992, 76:401-7. 10.1136\/bjo.76.7.401","journal-title":"Br J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/01.iop.0000232164.00208.b4","article-title":"Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland","volume":"22","author":"Esmaeli B","year":"2006","unstructured":"Esmaeli B, Golio D, Kies M, DeMonte F. Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2006, 22:366-70. 10.1097\/01.iop.0000232164.00208.b4","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24433","article-title":"Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma","volume":"38","author":"Esmaeli B","year":"2016","unstructured":"Esmaeli B, Yin VT, Hanna EY, Kies MS, William WN Jr, Bell D, Frank SJ. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2016, 38:1258-62. 10.1002\/hed.24433","journal-title":"Head Neck"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.3.315","article-title":"Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland","volume":"116","author":"Meldrum ML","year":"1998","unstructured":"Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol. 1998, 116:315-21. 10.1001\/archopht.116.3.315","journal-title":"Arch Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000158","article-title":"Intra-arterial chemotherapy for lacrimal gland adenoid cystic carcinoma","volume":"57","author":"Zhang M","year":"2017","unstructured":"Zhang M, Fathy C, Breazzano MP, Hollar M, Barahimi B. Intra-arterial chemotherapy for lacrimal gland adenoid cystic carcinoma. Int Ophthalmol Clin. 2017, 57:143-52. 10.1097\/IIO.0000000000000158","journal-title":"Int Ophthalmol Clin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.01.027","article-title":"Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma","volume":"120","author":"Tse DT","year":"2013","unstructured":"Tse DT, Kossler AL, Feuer WJ, Benedetto PW. Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2013, 120:1313-23. 10.1016\/j.ophtha.2013.01.027","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26558","article-title":"Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland","volume":"10","author":"Doddapaneni R","year":"2019","unstructured":"Doddapaneni R, Tao W, Naranjo A, Nikpoor N, Tse DT, Pelaez D. Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland. Oncotarget. 2019, 10:480-93. 10.18632\/oncotarget.26558","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omy066","article-title":"Lacrimal gland adenocarcinoma responding to checkpoint inhibition and androgen deprivation","volume":"2018","author":"Bulbul A","year":"2018","unstructured":"Bulbul A. Lacrimal gland adenocarcinoma responding to checkpoint inhibition and androgen deprivation. Oxf Med Case Reports. 2018, 2018:omy066. 10.1093\/omcr\/omy066","journal-title":"Oxf Med Case Reports"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001673","article-title":"Bilateral poorly differentiated adenocarcinoma of the lacrimal gland with tumor regression after treatment with pembrolizumab","volume":"36","author":"Tran AQ","year":"2020","unstructured":"Tran AQ, Choi CJ, Al-Sadah Z, Yi Zhou X, Dubovy S, Rothschild NE, Lee BW. Bilateral poorly differentiated adenocarcinoma of the lacrimal gland with tumor regression after treatment with pembrolizumab. Ophthalmic Plast Reconstr Surg. 2020, 36:e144-7. 10.1097\/IOP.0000000000001673","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001585","article-title":"PD-L1 and PD-L2 expression levels are low in primary and secondary adenoid cystic carcinomas of the orbit: therapeutic implications","volume":"36","author":"Wolkow N","year":"2020","unstructured":"Wolkow N, Jakobiec FA, Afrogheh AH, Kidd M, Eagle RC, Pai SI, Faquin WC. PD-L1 and PD-L2 expression levels are low in primary and secondary adenoid cystic carcinomas of the orbit: therapeutic implications. Ophthalmic Plast Reconstr Surg. 2020, 36:444-50. 10.1097\/IOP.0000000000001585","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1790106","article-title":"Ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland: a rare and morbid malignancy","volume":"2020","author":"Ashok Kumar P","year":"2020","unstructured":"Ashok Kumar P, Paulraj S, Mirchia K, Hahn SS, Sivapiragasam A. Ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland: a rare and morbid malignancy. Case Rep Oncol Med. 2020, 2020:1790106. 10.1155\/2020\/1790106","journal-title":"Case Rep Oncol Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_241_17","article-title":"Caruncular oncocytoma: report of two cases with review of literature","volume":"9","author":"Mitra S","year":"2018","unstructured":"Mitra S, Lath K, Samanta R, Saikia UN. Caruncular oncocytoma: report of two cases with review of literature. Indian Dermatol Online J. 2018, 9:324-7. 10.4103\/idoj.IDOJ_241_17","journal-title":"Indian Dermatol Online J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/105881-current-trends-in-the-management-of-epithelial-lacrimal-gland-tumors-a-retrospective-national-cancer-database-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:23Z","timestamp":1707507623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/105881-current-trends-in-the-management-of-epithelial-lacrimal-gland-tumors-a-retrospective-national-cancer-database-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.27109","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,21]]}}}